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A B S T R A C T
Background
Delirium is a syndrome characterised by a disturbance of consciousness (often fluctuating), cognition and perception. In terminally ill
patients it is one of the most common causes of admission to clinical care. Deliriummay arise from any number of causes and treatment
should be directed at addressing these causes rather than the symptom cluster. In cases where this is not possible, or treatment does not
prove successful, the use of drug therapy to manage the symptoms may become necessary. This is an update of the review published on
’Drug therapy for delirium in terminally ill adult patients’ in The Cochrane Library 2004, Issue 2 (Jackson 2004).
Objectives
To evaluate the effectiveness of drug therapies to treat delirium in adult patients in the terminal phase of a disease.
Search methods
We searched the following sources: CENTRAL (The Cochrane Library 2012, Issue 7), MEDLINE (1966 to 2012), EMBASE (1980 to
2012), CINAHL (1982 to 2012) and PSYCINFO (1990 to 2012).
Selection criteria
Prospective trials with or without randomisation or blinding involving the use of drug therapies for the treatment of delirium in adult
patients in the terminal phase of a disease.
Data collection and analysis
Two authors independently assessed trial quality using standardised methods and extracted trial data. We collected outcomes related to
efficacy and adverse effects.
Main results
One trial met the criteria for inclusion. In the 2012 update search we retrieved 3066 citations but identified no new trials. The included
trial evaluated 30 hospitalised AIDS patients receiving one of three agents: chlorpromazine, haloperidol and lorazepam. The trial under-
reported key methodological features. It found overall that patients in the chlorpromazine group and those in the haloperidol group
had fewer symptoms of delirium at follow-up (to below the diagnostic threshold using the Diagnostic and Statistical Manual of Mental
Disorders (DSM-III) and that both were equally effective (at two days mean difference (MD) 0.37; 95% confidence interval (CI) -
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4.58 to 5.32; between two and six days MD -0.21; 95% CI -5.35 to 4.93). Chlorpromazine and haloperidol were found to be no
different in improving cognitive status in the short term (at 48 hours) but at subsequent follow-up cognitive status was reduced in those
taking chlorpromazine. Improvements from baseline to day two for patients randomised to lorazepam were not apparent. All patients
on lorazepam (n = 6) developed adverse effects, including oversedation and increased confusion, leading to trial drug discontinuation.
Authors’ conclusions
There remains insufficient evidence to draw conclusions about the role of drug therapy in the treatment of delirium in terminally ill
patients. Thus, practitioners should continue to follow current clinical guidelines. Further research is essential.
P L A I N L A N G U A G E S U M M A R Y
Drug therapy for delirium in terminally ill adult patients
There is limited evidence from clinical trials on the role of drug therapy for the treatment of delirium in terminally ill patients. The key
feature of delirium is a decreased level of consciousness (awareness). People may experience impaired memory, thinking and judgement,
and become disorientated. They may experience distressing hallucinations or delusions. It occurs frequently in patients with terminal
illness, and may be caused by the illness itself or occur as a side effect of drug treatments for symptom management. Our search of
the international literature for trials of drug therapies for the treatment of delirium in patients with terminal illness yielded one small
study, and therefore it was not possible to assess the effectiveness of drug treatment options. It is hoped that this review will provide an
incentive for further research.
B A C K G R O U N D
This is an update of the review published on ’Drug therapy for
delirium in terminally ill adult patients’ in The Cochrane Library
2004, Issue 2 (Jackson 2004).
Delirium is a broad neuropsychiatric syndrome. It involves cere-
bral dysfunction and is characterised by disturbances of conscious-
ness and cognitive changes that cannot be accounted for by any
pre-existing or evolving dementia (DSM-IV-TR). It is often a
fluctuating state in which there are disturbances of attention, ori-
entation, thinking, perception, memory, psychomotor behaviour,
emotion and the sleep-wake cycle (Breitbart 2009). There are
three major types of delirium: hyperactive, hypoactive or mixed.
Hyperactive delirium is characterised by agitation and hallucina-
tions. Hypoactive delirium presents as a decreased level of con-
sciousness with somnolence. Delirium of a mixed type alternates
between agitated and hypoactive forms. The aetiology of delir-
ium is complex. It is commonly multifactorial and may arise
from: severe pain; metabolic encephalopathy; electrolyte abnor-
malities from dehydration or renal failure; infection such as pneu-
monia or urinary tract; haematological abnormalities; endocrine
or metabolic factors such as thyroid dysfunction or nutritional
deficits; paraneoplastic syndromes; cerebral tumour or cerebrovas-
cular disease; central nervous system metastases; seizure disorders;
hypoxia/anaemia; myocardial infarction or heart failure; constipa-
tion; urinary retention; and environmental factors such as sleep
deprivation and sensory deprivation, often secondary to visual and
hearing impairment. In addition, numerous drugs, drug with-
drawal or both (such as alcohol and sedatives) are known triggers
of delirium. In terminally ill patients opioids, antipsychotics, an-
ticholinergic agents, corticosteroids and antineoplastic agents can
cause delirium (Jackson 1999). Benzodiazepines, which are com-
monly used to treat delirium, can also contribute to its cause.
It is estimated that 90% of patients with advanced disease de-
velop delirium in the final weeks of life (Lawlor 2000). At this ad-
vanced stage of disease it is one of the main reasons for admission
to a palliative care unit (Cobb 2000) and constitutes one of the
most important mental disorders at the end of life because of its
high prevalence and deleterious impact on the patient’s quality of
life, behaviour and communication, and on the patient’s family
(Ganzini 2008). However, the syndrome is likely to be under di-
agnosed in terminally ill patients. Hypoactive deliriummay be the
most common presentation in advanced disease, where it may be
mistaken for lowmood or sedation due to opioids (Meagher 2011;
Spiller 2006). Delirium may also be confused with dementia, as
it can present as impaired memory, thinking and judgement, and
disorientation. However, it differs from dementia in that delir-
ium is usually more acute in presentation, often has a fluctuating
course, there is a decreased level of consciousness and it may be
2Drug therapy for delirium in terminally ill adult patients (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
reversed with treatment.
Treatment of delirium is possible in terminally ill patients (de
Stoutz 1995; Moyer 2011), with estimates of the potential re-
versibility of delirium of up to 50% (Gagnon 2012; Lawlor 2000).
However, treatment may not be possible in the last 24 to 48 hours
of life because of irreversible processes such as multiple organ fail-
ure and metabolic abnormalities. At this stage management be-
comes increasingly challenging as the patientmay appear distressed
or suffer from heightened behavioural manifestations, such as in-
voluntary muscle twitching or jerks and restlessness. They may
also experience spiritual, emotional or physical anguish, anxiety
and cognitive failure. This combination of distressing symptoms
has been described as agitated delirium, terminal delirium, termi-
nal restlessness, terminal agitation, existential distress or terminal
distress.
The best treatment approach for terminally ill patients, including
those in the last 48 hours of life, is attention to the underlying
causes. However, finding the cause of delirium can be difficult and
even when this is established, treatment may be limited because
delirium may not be reversible (for example in the case of brain
metastases). Moreover, the context or place of care (for example if
a person is living at home) may preclude treatment since comfort
should be the priority, with unpleasant or painful diagnostic pro-
cedures avoided if at all possible.
Management of delirium involves non-pharmacological treat-
ments, including nursing the patient in a stable environment with
continuity of care and a multidisciplinary team approach (Cotton
2011; Inouye 2006). It also involves appropriate lighting for time
of day, reduction of noise, efforts to establish a good diet and hy-
dration, a regular sleep pattern, analgesic review, adequate oxygen
delivery and, if possible, engagement in social activities (Cotton
2011; Inouye 2006).However, supportive techniques alone are not
always effective in controlling symptoms of delirium and a phar-
macological intervention may be required. Medications currently
used in clinical practice include neuroleptics (e.g. haloperidol,
thioridazine, chlorpromazine and methotrimeprazine), benzodi-
azepines (e.g. lorazepam and midazolam) and levomepromazine.
Haloperidol is often cited as the drug of choice for the treatment
of delirium (Breitbart 2000; Ingham 1998; NHS Scotland 2009;
NICE 2010; Roth 1996). Other medications have also been ex-
plored, including psychostimulants (Keen 2004).
When a patient is in the last hours of life, drugs to induce sedation
are commonly prescribed to manage distress. Deep sedation may
be an option to ensure comfort in the final hours (Cherny 2009).
However, therapy to manage delirium is not without controversy;
some have argued that in the dying phase drug therapy is inappro-
priate, as delirium can be viewed as part of this process and that
hallucinations may be pleasant and comforting (Breitbart 2009).
There are also concerns that some drug treatments may worsen
symptoms and hasten death. In addition, some have argued that
treating delirium and restoring lucidity to a dying person may in-
crease their distress.
There are clinical guidelines on the treatment of delirium in the
terminally ill (National Cancer Institute 2011; NHS Scotland
2009). There is also a number of (non-systematic) review articles
on the treatment of delirium (Breitbart 2000; Caraaceni 2009;
Cotton 2011; de Stoutz 1995; Inouye 2006; Moyer 2011).
O B J E C T I V E S
To evaluate controlled trials evaluating the effectiveness of drug
therapies in the treatment of delirium in patients in the terminal
phase of a disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised and non-randomised trials comparing any drug treat-
ment with other treatments for delirium in patients with terminal
disease. Trials could be conducted in any setting.
Types of participants
Terminally ill adult patients (18 years or older) with delirium. This
included trials whose participants were described as having termi-
nal agitation, terminal distress or terminal restlessness. Whilst we
relied on the trials’ descriptions of a patient having delirium, in all
cases we sought to verify that the disorder being treated qualified
as a form of delirium as defined by the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV-TR or earlier versions) or
the short Confusion Assessment Method (Inouye 2003).
The definition of terminal illness is not always clear, therefore stud-
ies for evaluation included patients with life-limiting disease (e.g.
advanced cancer); those who were receiving hospice or palliative
care or those who had end-stage disease. We included participants
at all stages of a terminal illness including the dying phase.
Types of interventions
Studies were included if they compared any drug therapy for
the treatment of delirium with another pharmacological agent
or a non-pharmacological approach. Specific pharmacological
agents included: barbiturates, benzodiazepines, butyrophenones,
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cholinesterase inhibitors, central nervous system stimulants, chlor-
promazine, haloperidol, isoxazoles, methotrimeprazine, midazo-
lam, olanzapine, piperidines, propofol, risperidone and thiori-
dazine.
Types of outcome measures
Primary outcomes
The primary outcome was a reduction in the symptoms of delir-
ium, such as an improvement in consciousness, cognition, atten-
tion and perception. These symptomsmay have beenmeasured us-
ing theDelirium Rating Scale (DRS) (Trzepacz 2001), theMemo-
rial Delirium Assessment Scale (Breitbart 1997) and the Delirium
Index (McCuster 1988).
Secondary outcomes
Secondary outcomes were adverse effects such as extrapyramidal
effects of dystonic or dyskinetic symptoms, oversedation and para-
doxical agitation.
Search methods for identification of studies
Electronic searches
To identify studies for inclusion we developed detailed search
strategies for each electronic database. See Appendix 1 for the 2012
update search strategy for MEDLINE.
Citation databases searched
1. Cochrane Central Register of Controlled Trials
(CENTRAL), in The Cochrane Library (2012, Issue 7)
2. MEDLINE (1966 to August 2012)
3. EMBASE (1980 to August 2012)
4. CINAHL (1982 to August 2012)
5. PSYCINFO (1990 to August 2012)
Trial registers searched
1. ClinicalTrials.gov
2. MetaRegister of controlled trials
3. ISRCTN Trials Register www.controlled-trials.com/isrctn
4. Netherlands Trial Register: www.trialregister.nl/trialreg/
index.asp
5. NIHR Clinical Research Portfolio Database: http://
public.ukcrn.org.uk/search/
6. UMIN Japan Trial Register: www.umin.ac.jp/ctr
7. UK Clinical Trials Gateway: www.ukctg.nihr.ac.uk/
8. WHO Portal (covers ClinicalTrials.gov; ISRCTN;
Australian and New Zealand Clincal Trial Registry; Chinese
Clinical Trial Register; India Clinical Trials Registry; German
Clinical trials Register; Iranian Registry of Clinical Trials; Sri
Lanka Clinical Trials Registry; The Netherlands National Trial
Register): www.who.int/trialsearch
Pharmaceutical industry trials registers searched
1. AstraZeneca Clinical Trials:
www.astrazenecaclinicaltrials.com
2. Daiichi Sankyo: www.daiichisankyo.com
3. Eisai: www.eisai.com
4. GlaxoSmithKline Clinical Trial Register: www.gsk-
clinicalstudyregister.com
5. Lundbeck: www.lunbeck.com
6. NovartisClinicalTrials.com: www.novartisclinicaltrials.com/
webapp/etrials/home.do
7. Roche Clinical Trial Protocol Registry: www.roche-
trials.com
Searching other resources
Reference lists
We searched the reference lists and forward citations of review
articles and any study included in the review for additional studies
and references.
Unpublished data
We did not seek unpublished studies.
Conference abstracts
We searched the annual conferences of the European Palliative
Care Association 2003 to 2011.
Language
We included all relevant studies regardless of language of publica-
tion.
Data collection and analysis
Selection of studies
In the original review, citations were screened by one review au-
thor (KCJ). In the 2012 update, two review authors (LJ and BC)
independently screened citations and full-text copies of potentially
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relevant studies. If any disagreements on study inclusion occurred
we planned that they would be resolved by discussion between all
review authors.
Data extraction and management
We designed a data extraction form, and the following data items
were extracted by one review author (KCJ) and checked by another
(BC/LJ/BL).
1. Publication details
2. Patient characteristics (number of patients included in the
trial, age, gender, performance status, etc.) and study setting (e.g.
hospice)
3. Trial methodology
4. Description of pharmacological intervention
5. Description of instrument used to evaluate delirium
6. Results
7. Study withdrawals/patient attrition
8. Adverse effects
Assessment of risk of bias in included studies
We assessed the risk of bias of included trials in accordance with the
criteria described in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
We assessed these using The Cochrane Collaboration’s ’Risk of
bias’ instrument. The instrument assesses six domains as follows.
• Randomisation allocation sequence generation.
• Concealment of allocation sequence.
• Blinding of participants, personnel and outcome assessors.
• The level of completeness of outcome data.
• Selective outcome reporting.
• Other sources of bias.
Each domain is assessed by whether the criteria for that domain
have been met (i.e. low risk of bias), whether they have not (i.e.
high risk of bias) or whether it is judged ’unclear’ whether they
have been met because of insufficient reporting.
Based on this criteria, we categorised a trial as:
a) all quality criteria met: low risk of bias;
b) one or more of the quality criteria only partly met: moderate
risk of bias; and
c) one or more criteria not met: high risk of bias.
In the 2012 update this was undertaken by one review author (BC)
and checked by another (BL). If differences of opinion existed we
planned to resolve them by consensus with one of the other review
authors.
Measures of treatment effect
Studies measuring treatment effect could involve dichotomous or
ordinal data. If dichotomous data had been reported, we would
have sought to extract or generate odds ratios (ORs) and their 95%
confidence intervals (CI). We assessed effect measures for ordinal
data as continuous data and, if fully reported, generated the mean
difference (MD) between trial arms.
Dealing with missing data
Missing studies can result from an inadequate search for data or
from publication bias in that papers with negative findings are less
likely to be published. How we dealt with this, or planned to deal
with this, is described in Assessment of reporting biases and Search
methods for identification of studies.
Due to participants’ declining health a significant amount of loss
to follow-up was expected to have occurred in any included trial.
We report attrition rates in the ’Risk of bias’ tables. This included,
if available, per trial arm reasons for attrition and whether the trial
stated any re-inclusions performed in analyses.
A common itemmissing in outcome data is the standard deviation
(SD) for continuous outcomes. If data were not reported, but
might have been available, we planned to contact the study authors
if the study had been published in the last 10 years. If contact with
the authors was not possible, we planned to calculate or impute
data using relevant data that were available.
We did not exclude trials on the basis of missing data.
Assessment of heterogeneity
If meta-analysis had been possible, we would have assessed sta-
tistical heterogeneity between trials using the Chi² test and the
I² statistic (a Chi² P value of less than 0.05 indicates significant
heterogeneity and an I² value greater than 50% indicates substan-
tial variability in the effect estimate between trials that is due to
heterogeneity). If heterogeneity was identified we planned to un-
dertake subgroup analysis to explore the lack of homogeneity.
Assessment of reporting biases
If meta-analysis had been possible we planned to explore publica-
tion bias by using funnel plots.
Data synthesis
We planned that if data from trials were of sufficient quality and
sufficiently similar (in terms of patient population, diagnostic cri-
teria, intervention, outcomemeasure, length of follow-up and type
of analysis) we would combine data in a meta-analysis to provide a
pooled effect estimate. A fixed-effect model would be used in the
first instance. If there was no statistical heterogeneity, we would
have used a random-effects model to check the robustness of the
fixed-effect model. If statistical heterogeneity was observed, we
would have used the random-effects model a priori.
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Subgroup analysis and investigation of heterogeneity
To explore clinical heterogeneity and investigate the effect modi-
fication of participants and treatment types, we planned, if suffi-
cient data had been available, to perform the following subgroup
analyses:
Participants
1. Type of disease, for example cancer, HIV or cardiovascular
disease
2. Age group
3. Type of delirium
Intervention
1. Type of drug therapy
Sensitivity analysis
We planned, if sufficient data had been available, to perform sen-
sitivity analyses by excluding:
1. unpublished studies (if there were any);
2. studies with a higher risk of bias;
3. studies that used scales that were not validated to measure
effect.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
In the original review 13 potential studies were identified by the
citation search strategy. Of these, at full paper retrieval, one met
the criteria for inclusion (Breitbart 1996a). From the 2012 update
searches across the main citation databases we screened 3066 cita-
tions. Four potential studies were identified, none of which were
relevant following full paper retrieval. The reasons for excluding
the total of 17 studies following full-text retrieval are described in
the Characteristics of excluded studies table. The most common
reason was the study not being a controlled trial. Searching of the
clinical trial databases identified (in ClinicalTrials.gov) one eligible
ongoing trial (Verheul 2009); this trial compares the effectiveness
of olanzapine with haloperidol in advanced cancer patients with
delirium. The current progress of this trial is unclear, as it was not
possible to contact the author.
Included studies
The one relevant completed trial compared the effects of chlor-
promazine, haloperidol and lorazepam in AIDS patients who were
hospitalised to treatmedical co-morbidities (Breitbart 1996a). The
participants met the DSM-III-R criteria (current at the time) for
delirium, and scored 13 or more on the Delirium Rating Scale
(DRS). They fulfilled our criteria of terminal illness because their
disease was at an advanced stage in that they had developed vari-
ous and multiple moderate to severe medical co-morbidities that
required medical treatment.
A total of 244 patients consented to participate in the trial, were
they to develop delirium during follow-up. Delirium occurred
in 30 patients, who were randomised to one of the three drug
treatments. Twenty-three patients were male and seven female. At
baseline the mean age was 39.2 years (SD 8.8, range 23 to 56) and
the mean Karnofsky Performance Score was 52.3 (SD 21.3, range
10 to 90). Patients had an average of 12moderate to severemedical
conditions (SD 4.1, range 6 to 22); these included septicaemia,
pneumocystis carinii pneumonia and tuberculosis. The authors do
not specify whether patients presented with a particular subtype
of delirium.
Thirteen patients were initially randomised to chlorpromazine, 11
to haloperidol and six to lorazepam. During the course of the in-
tervention the lorazepam trial arm was dropped because of adverse
effects. Patients who had been in this group were randomised to
either haloperidol or chlorpromazine; the authors do provide de-
tails on the numbers randomised to each of these groups.
The trial used a drug-dosing protocol, (see Table 1). Patients were
evaluated an hour after receiving a trial drug. If their DRS score
was13 or greater, they were given the drug dose at the next level.
Once stabilisation occurred, defined as asleep, calm, not halluci-
nating or a score of 12 or less on the DRS, patients were kept on a
twice daily maintenance dose for up to six days. No information
was provided on the average length of therapy, nor was informa-
tion provided as to the criteria used for discontinuing drug ther-
apy.
Mean drug doses during the first 24 hours were:
• haloperidol 2.8 mg (SD 2.4, range 0.8 to 6.3);
• chlorpromazine 50 mg (SD 23.1, range 10 to 70);
• lorazepam 3 mg (SD 3.6, range 0.5 to 10).
Average maintenance doses were:
• haloperidol 1.4 mg (SD 1.2, range 0.4 to 3.6);
• chlorpromazine 36 mg (SD 18.4, range 10 to 80);
• lorazepam 4.6 mg (SD 4.7, range 1.3 to 7.9).
Risk of bias in included studies
The trial is at a moderate risk of biased results as it under-reports
key methodological features, including how the randomisation
sequence was generated and who was blinded, e.g. whether the
interventionist and the analyst were both blinded. Furthermore,
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a second randomisation of those withdrawn from the lorazepam
arm makes the findings hard to interpret.
Effects of interventions
Symptoms of delirium
The trial found that both chlorpromazine and haloperidol reduced
the symptoms of delirium in the short term . The mean values in
both groupswere reduced below theDSM-III diagnostic threshold
for delirium as measured by the Delirium Rating Scale (DRS)
(for haloperidol at baseline: 20.45 (SD 3.45), at day two: 12.45
(SD 5.87) and at day six: 11.64 (SD 6.10); for chlorpromazine
at baseline: 20.62 (SD 3.88), at day two: 12.08 (SD 6.50) and at
day six: 11.85 (SD 6.74)). No significant differences were found
between the two drugs (day two: mean difference (MD) 0.37;
95% confidence interval (CI) -4.58 to 5.32; days two to six MD
-0.21; 95% CI -5.35 to 4.93). In comparison with lorazepam,
both chlorpromazine and haloperidol significantly reduced the
symptoms of delirium at day two (MD -5.25; 95% CI -10.12 to
-0.38; MD -4.88; 95% CI -9.70 to -0.06, respectively).
Improvements in delirium from baseline to day two for patients
randomised to lorazepam were not apparent (at baseline: 18.33
(SD 2.58) and at two days: 17.33 (SD 4.18)). The lorazepam arm
was stopped early due to adverse effects.
Cognitive status
At day two patients in the chlorpromazine and haloperidol group
had improved cognitive status, as measured by the Mini-Mental
State Examination (for haloperidol from 13.45 (SD 6.95) at base-
line to 17.27 (SD 8.87) at day two); for chlorpromazine from
10.92 (SD 8.87) at baseline to 18.31 (SD 10.61) at day two).
They were found to be equally effective (MD -1.04; 95% CI -
8.83 to 6.75). At subsequent follow-up, at day six, for chlorpro-
mazine there was a decrease in cognition but not for haloperidol;
the Mini-Mental State Examination remained stable (15.08 (SD
10.43); 17.18 (SD 12.12), respectively).
Patients receiving lorazepam at day two showed a decrease in cog-
nitive status (at baseline: 15.17 (SD 5.31); at day two: 12.67 (SD
10.23)).
Adverse effects
All patients in the lorazepam trial arm (n = 6) developed side ef-
fects, including oversedation and increased confusion. The side
effects led to refusal to take the drug or required drug discontinu-
ation. In patients in the chlorpromazine and the haloperidol trial
arms no clinically significant side effects were noted and scores on
the Parkinsonism subscale of the Extrapyramidal Symptom Rat-
ing Scale were reported as extremely low (see Table 2).
D I S C U S S I O N
Summary of main results
This review aimed to evaluate the effectiveness of drug therapies in
the treatment of patients suffering fromdeliriumduring the termi-
nal phase of a disease. It found limited clinical trial data available.
In one small trial in participants with advanced AIDS there was
no significant difference in the effect of treatment for delirium be-
tween haloperidol and chlorpromazine; both reduced symptoms
to below the DSM-III (current at the time of the trial) diagnostic
threshold for delirium. Within the first 48 hours patients receiv-
ing haloperidol or chlorpromazine also showed an improvement
in cognition, but subsequently there was a decrease in cognitive
function in those taking chlorpromazine. Both drugs were accept-
able and well tolerated. In the trial lorazepam was found not to
benefit the six patients randomised to the drug, and all patients
were withdrawn from the drug during the trial because of side
effects, including increased confusion.
Overall completeness and applicability of
evidence
The evidence found in this review is limited as it is from one
small trial with methodological shortcomings. The trial does not
report the subtype(s) of delirium in the participants, i.e. hyper-
active, hypoactive or fluctuating. Differences in subtype between
the trial arms may have influenced the findings. Furthermore, the
presumed improvement of some patients to sub-threshold DSM-
III deliriummay have been due to sedation of hyperactive delirium
into a state of hypoactive delirium. This is a common issue with
many delirium intervention studies. In addition, distress was not
measured as an outcome so we are unable to establish the wider
clinical benefits of this intervention. The applicability of the ev-
idence found here to other populations of terminally ill patients
is limited, as the results may not be transferable to patients with
other diseases because of disease mechanisms specific to AIDS. In
addition, the absence of placebo control arm does not allow us to
evaluate fully the efficacy of the drugs.
It is somewhat surprising that no new trials have been completed
since the original review was completed in 2004, however there are
ethical and practical issues that make it extremely challenging to
conduct randomised trials in terminally ill populations. Further-
more, the point at which consent is obtained is a problem. In the
one trial reported in this review, 244 patients agreed to participate
but only 30 became eligible by developing delirium.
There are other Cochrane reviews on drug therapy for delirium,
however their focus was not on a specific type of patient group
(Lonergan 2007; Lonergan 2009; Overshott 2008). They too
found limited trial evidence, but as delirium in terminally ill pa-
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tients is likely to be different in aetiology and in treatment the
applicability of this evidence, if there were any, would be limited.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is very limited evidence on the role of drug therapies for
the reduction of delirium in terminally ill patients and therefore
this review cannot make recommendations specific to this patient
group. Given little evidence of harm from drugs currently used
in day-to-day clinical palliative care practice (apart from this one
small trial that showed adverse effects with lorazepam), their use
is likely to continue and is supported by clinical guidelines on
the treatment of delirium in terminally ill adults (for example,
National Cancer Institute 2011; NHS Scotland 2009). However,
these recommend that drug therapy is not a first option in the
management of this patient group and also recommend that the
identification and treatment of the cause should be prioritised and
supportive strategies considered. Key components of these guide-
lines include reviewing all medication and stopping non-essential
drugs, maintaining hydration, controlling pain, promoting good
sleep patterns, re-orientating patients frequently, improving oral
nutrition and mobility, checking for opioid toxicity, checking for
infection, constipation and urinary problems, and reviewing the
full blood count and biochemistry. If medication is essential to
control symptoms then the aims of treatment should be deter-
mined by the multi-professional team and patient’s family or sup-
porters. In patients who are near to death, experiencing severe
distress and suffering, and whose symptoms of delirium are not
relieved by standard approaches, a clinician may consider follow-
ing the European Association for Palliative Care’s recommended
framework for the use of sedation in palliative care (Cherny 2009).
Implications for research
The lack of trials evaluatingdrug therapy for delirium in terminally
ill patients deserves further attention. Ethically and practically it
would be challenging to conduct a placebo-controlled randomised
trial. Instead, larger multi-centred controlled trials are needed to
compare effects of alternative drug therapies for delirium in ter-
minally ill adult patients. All further trials should fully report their
methods and also the characteristics of the participants, including
the delirium subtype and changes in clinically meaningful symp-
toms such as distress and discomfort. Future trials should consider
flexible dosing schedules or combination regimens, which reflect
everyday clinical practice. Although beyond the focus of this re-
view, there is also the need for research in other areas, including a
better understanding of factors involved in reversing delirium, the
use of non-drug therapy interventions and the role of sedation in
the management of delirium.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Breitbart 1996a
Methods Randomised, parallel controlled trial
Participants Hospitalised AIDS patients (n = 30, 23 male, 7 female)
Mean age 39.2 years (SD 8.8, range 23 to 56)
All met DSM-III-R criteria for delirium and scored 13 or greater on theDelirium Rating
Scale (DRS). Mean Karnofsky Performance Score at baseline was 52.3 (SD 21.3, range
10 to 90). The Medical Status Profile showed patients to have a mean of 12.57 medical
conditions (SD 4.1, range 6 to 22)
Interventions Intervention 1: haloperidol; mean drug doses during the first 24 hours: 2.8 mg (SD 2.
4), average maintenance dose 1.4 mg (SD 1.2), n = 11
Intervention 2: chlorpromazine; mean drug doses during the first 24 hours: 50 mg (SD
23.1), average maintenance dose 36 mg (SD 18.4), n = 13
Intervention 3: lorazepam; mean drug doses during the first 24 hours: 3 mg (SD 4.7),
average maintenance dose 4.6 mg (SD 4.7), n = 6
3-drug study utilising dose level protocol
Assessment every hour until stabilisation
Lorazepam arm stopped early due to adverse effects
Outcomes DRS scores
MMSE scores
Extrapyramidal Symptom Rating Scale scores
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised by hospital pharmacy
Allocation concealment (selection bias) Low risk Randomised by hospital pharmacy
Incomplete outcome data (attrition bias)
All outcomes
Low risk In all trial arms some of the participants died
during treatment (2 chlorpromazine, 2 haloperi-
dol, 1 lorazepam). This is to expected in this pa-
tient group who are in the advanced stages of a
terminal disease
Selective reporting (reporting bias) Unclear risk No information provided
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Breitbart 1996a (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States “double blinded” but does not state who
was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk States “double blinded” but does not state who
was blinded
DRS: Delirium Rating Scale
DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders III (revision)
MMSE: Mini-Mental State Examination
SD: standard deviation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adams 1984 Not a randomised controlled trial
Adams 1986 Not a randomised controlled trial
Akechi 1996 Not a randomised controlled trial
Breitbart 2002 Not a randomised controlled trial
Bruera 1992 Patient did not have delirium
Burke 1991 Not a prospective controlled clinical trial; retrospective analysis
Cobb 2000 Not a prospective controlled clinical trial; retrospective analysis
Fainsinger 2000 Not a prospective controlled clinical trial; retrospective analysis
Han 2004 Patients were not terminally ill
Lawlor 2000 Not a prospective controlled clinical trial; descriptive study without comparative drug or treatment arms
Maddocks 1996 Not a prospective controlled clinical trial; prospective cohort study
McIver 1994 Not a prospective controlled clinical trial; descriptive study without comparative drug or treatment arms
Mercadante 2001 Patients did not have delirium
Oliver 1985 Not a prospective controlled clinical trial; retrospective survey
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(Continued)
Olofsson 1996 Not a prospective controlled clinical trial; retrospective survey
Pereira 1997 Not a prospective controlled clinical trial; retrospective survey
Stiefel 1992 Not a prospective controlled clinical trial; retrospective analysis
Characteristics of ongoing studies [ordered by study ID]
Verheul 2009
Trial name or title Early recognition and optimal treatment of delirium in patients with advanced cancer
Methods Randomised controlled trial
Participants Advanced cancer patients admitted to medical oncology
When diagnosis of delirium is confirmed patients will be randomised
Interventions Olanzapine versus haloperidol (usual care)
Outcomes Patients who recover from delirium and their caregivers will be asked to complete the Delirium Experience
Questionnaire
Starting date 2009
Contact information h.verheul@vumc.nl
Notes Source: ClinicalTrials.gov
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Dosing protocol
Dose level Haloperidol Chlorpromazine Lorazepam
1 0.25 mg oral or 0.125 mg IM 10 mg oral or 5 mg IM 0.5 mg oral or 0.2 mg IM
2 0.5 mg oral or 0.5 mg IM 20 mg oral or 10 mg IM 1.0 mg oral or 0.5 mg IM
3 1.0 mg oral or 0.5 mg IM 40 mg oral or 20 mg IM 1.5 mg oral or 0.7 mg IM
4 2.0 mg oral or 1.0 mg IM 80 mg oral or 40 mg IM 2.0 mg oral or 1.0 mg IM
5 2.5 mg oral or 1.5 mg IM 100 mg oral or 50 mg IM 2.5 mg oral or 1.25 mg IM
6 2.5 mg oral or 1.5 mg IM 100 mg oral or 50 mg IM 2.5 mg oral or 1.25 mg IM
7 2.5 mg oral or 1.5 mg IM 100 mg oral or 50 mg IM 2.5 mg oral or 1.25 mg IM
8 5.0 mg oral or 3.0 mg IM 200 mg oral or 100 mg IM 4.0 mg oral or 2.0 mg IM
9 5.0 mg oral or 3.0 mg IM 200 mg oral or 100 mg IM 4.0 mg oral or 2.0 mg IM
IM: intramuscular
Table 2. Extrapyramidal Symptom Rating Scale scores
ESRS score Baseline End of therapy
Chlorpromazine (n = 13 patients) 7.42 (SD 8.08) 5.08 (SD 4.48)
Haloperidol (n = 11 patients) 7.0 (SD 6.8) 5.54 (SD 6.76)
Lorazepam (n = 6 patients) 7.6 (SD 10.11) 12.2 (SD 8.93)
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
The subject search used a combination of controlled vocabulary and free-text terms in addition to the Cochrane Collaboration’s
’Sensitive search strategy’. The terms used in the 2011 update are population, disease, individual treatments and drug class names, as
listed below.
Population
Terminal or advanced disease or palliative
Disease
delirium or agitation or acute confusional state or distress or diminished consciousness or disturbed consciousness or disordered con-
sciousness or cognitive dysfunction or disturbed cognition or disordered cognition or change in cognition or failure of cognition or
abnormalities of cognition or disturbed perception or disordered perception or change in perception or abnormalities of perception
or change in attention or disturbed attention or disordered attention or abnormalities of attention or acute brain syndrome or en-
cephalopathy or organic mental disorders or acute cerebral insufficiency or restlessness
Individual treatments
Alprazolam or aminotriazole or amisulpride or solian or amobarbital or aricep or taripiprazole or abilify or ativan or benperidol
or anquil or bromazepam or chlordiazepam or chlordiazepoxide or citicoline or clobazepam or clobazam or cognex or clonidine or
dexamphetamine or eclozapine or clozaril or denzapinemor zaponex or clonazepamor chlordiazepamor chlorfiazepoxide or chlorazepate
or chlorpromazine or dexmedetomidine or dexemetomidine or diazepamor donepezil or droperidol or emethotrimeprazin or eestazolam
or exelon or flunitrazepam or flupentixol or depixol or fluanxol or fluphenazine or flurazepam or dalmane or gabapentin or galantamine
or halazepam or haloperidol or dozic or haldol or serenace or iloperidone or ketazolam or levomepromazine or nozinan or lorazepam
or ativan or lormetazepam or mesoridazine or methotrimeprazine or methylphenidate or midazolam or modafinil or nitrazepam or
nitrous oxide or olanzapine or zyprexa or oxazepam or paliperidone or invega or periciazine or pericyazine or perphenazine or fentazin
or phenobarbitone or pimozide or orap or pipotiazine or prazepam or prochlorperazine or propofol or promazine or promethazine
or quazepam or quetiapine or seroquel or reminyl or risperidone or risperdal or rivastigmine or sertindole or leponex or zeldox or
sulpiride or dolmatil or sulpor or tacrine or temazepam or thiopental or thioridazine or trifluoperazine or stelazine or triflupromazine
or triazolam or valium or ziprasidone or zotepine or zuclopenthixol or clopixol
Drug class names
Antipsychotics or neuroleptics or major tranquillisers or anxiolytics or barbiturates or benzisoxazole or benzodiazepines or buty-
rophenones or cholinesterase inhibitors or phenothiazines or psychostimulants or central nervous system stimulants or diphenyl-
butylpiperidines or thienobenzodiazepine or thioxanthenes or substituted benzamides
WH A T ’ S N E W
Last assessed as up-to-date: 1 June 2012.
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Date Event Description
20 September 2012 New citation required but conclusions have not
changed
Assessed as up to date.
1 June 2012 New search has been performed New searches and assessed as up to date.
H I S T O R Y
Protocol first published: Issue 2, 2004
Review first published: Issue 2, 2004
Date Event Description
1 June 2011 New search has been performed New searches were run. We also updated all sections.
12 August 2009 Amended Contact details updated.
27 October 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
In the original review: KCJ was primary review author and AL secondary review author.
In 2012 update KCJ, AT, MK, LJ and BC updated the search strategy. BC and LJ independently screened the citation searches and
assessed the eligibility of any full papers retrieved following screening. BC drafted the review. BL provided advice and support for
statistical analysis and commentary on the findings. KCJ, AT, MK, LJ and BL commented on the draft review. All authors agreed the
final document.
D E C L A R A T I O N S O F I N T E R E S T
None known.
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S O U R C E S O F S U P P O R T
Internal sources
• Texas Tech HSC School of Pharmacy Department of Pharmacy Practice, USA.
• University of Utah College of Pharmacy Department of Pharmacy Practice, USA.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For the 2012 update we ran a new search and updated the background, methods, results and discussion to comply with current
Cochrane requirements.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antipsychotic Agents [therapeutic use]; Chlorpromazine [therapeutic use]; Delirium [∗drug therapy; etiology];Haloperidol [therapeutic
use]; Lorazepam [therapeutic use]; Randomized Controlled Trials as Topic; Terminally Ill [∗psychology]
MeSH check words
Adult; Humans
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